Zai Lab LtdZLAB

時価総額

$279.3億

PER

バイオ医薬品の有力企業。オンコロジーを中心とした研究開発と商用化済み製品7件を展開。2019年のDeciphera契約や2021年のargenx提携などのライセンス実績。中国本土・香港・マカオ中心の展開。

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-50,384,176	-139,074,895	-195	-269	-704	-443	-335	-257
Allowance for credit losses	-	-	-	0	0	0	0	0
Inventory write-down	-	-	-	0	1	0	1	1
Depreciation and amortization expenses	-	-	4	5	6	8	9	12
Tangible Asset Impairment Charges	-	-	-	-	-	-	0	-
Amortization of deferred income	-	-312,000	-0	-0	-1	-3	-3	-4
Share-based compensation	10	12	20	25	41	61	80	71
Share of loss from equity method investment	-249,652	-586,551	-	-1	-1	-0	-	-
Loss (gain) from fair value changes of equity investment with readily determinable fair value	-	-	-	-	-	-	3	-6
Losses on disposal of property and equipment	-12,961	-704	-0	0	-0	-1	-0	-0
Gain on disposal of land use right	-	-	-	-	-	-	0	-
Noncash lease expenses	-	-	3	4	6	8	9	8
Gain from sale of intellectual property	-	-	-	-	-	-	10	-
Foreign currency remeasurement impact	-	-	-	-	-	-56	-15	-15
Amortization of debt issuance cost	-	-	-	-	-	-	-	1
Accounts receivable	-	89,708	4	1	42	-4	20	27
Notes receivable	-	-	-	-	7	2	-2	-2
Inventories	-	3,822	6	7	7	15	15	-4
Prepayments and other current assets	810,979	5	1	4	7	19	-12	19
Long-term deposits	38,845	249,913	-0	0	0	1	-0	0
Value added tax recoverable	-	-	-	8	2	-23	-	1
Accounts payable	8	28	-15	40	64	-54	37	-2
Other current liabilities	-	-	9	-11	19	7	20	-22
Operating lease liabilities	-	-	-2	-3	-5	-8	-8	-9
Deferred income	2	-	-	14	11	-1	11	7
Other non-current liabilities	-	-	-	-	-	-	0	-
Net cash used in operating activities	-	-97,538,022	-191	-216	-549	-368	-198	-215
Purchases of short-term investments	-	200	278	949	445	260	134	330
Proceeds from maturity of short-term investments	-	-	-	-	-	705	118	16
Purchases of property and equipment	9	10	6	10	18	25	7	6
Proceeds from the sale of property and equipment	82,789	-	-	-	0	-	0	0
Acquisition of intangible assets	14,690	102,834	1	1	1	0	1	56
Proceeds from Sale of Intangible Assets	-	-	-	-	-	-	10	-
Proceeds from disposal of land use right	-	-	-	-	-	-	4	-
Net cash (used in) provided by investing activities	-	-212,553,897	-15	-555	250	420	-11	-375
Proceeds from short-term debt	-	4	7	-	-	-	-	132
Repayment of short-term bank borrowings	-	-	4	7	-	-	-	0
Payment of debt issuance cost	-	-	-	-	-	-	-	1
Proceeds from Stock Options Exercised	65,500	195,711	1	7	7	6	2	3
Proceeds from Issuance of Common Stock	-	-	-	-	-	-	-	217
Payments of public offering costs	3	691,527	1	5	2	-	-	1
Taxes paid related to settlement of equity awards	-	-	-	-	-	-	9	-
Net cash provided by (used in) financing activities	-	144	219	1,132	820	-2	-6	350
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	-	-	0	5	1	-6	-3	-0
Net (decrease) increase in cash, cash equivalents and restricted cash	-	-	13	366	522	44	-218	-240
Cash paid for interest	-	35,799	0	0	-	-	-	2
Payables for purchase of property and equipment	413,657	2	0	1	3	5	2	0
Non Cash Payables For Intangible Assets	-	225,158	-	0	0	0	12	3
Payables for public offering costs	-	-	-	-	-	-	-	1
Right-of-use asset acquired under operating leases	-	-	-	-	-	15	4	15
Receivables for stock option exercise under equity incentive plans	-	-	-	-	-	-	-	0